Explore the latest in pharmocogenetics, including advances in personalized medicine from genetic markers of drug efficacy and adverse effects.
This survey study investigates trends in statin use and expenditures after market exclusivity ended and generic statins became available in the US.
This cohort study assesses the implementation outcomes of a pharmacogenomic testing program comprising a point-of-care model evaluating targeted drugs and a preemptive model using whole-genome sequencing to evaluate potential drug therapies among children in a pediatric tertiary care setting.
This Viewpoint describes the concept of precision drug dosing, which would maximize drug benefit and minimize harm for each patient, and reviews the scientific, regulatory, technical, and practical infrastructures that would need to be in place for the idea to become reality in clinical practice settings.
This Viewpoint uses examples of recommendations for race-based pharmacogenetic testing to discuss flaws and inconsistencies with race and ethnicity as surrogates for biology, and the consequences of those deficiencies for clinical decision-making.
This cross-sectional study assesses potential opportunities for genotype-guided prescribing in pediatric populations among multiple health systems by examining the prevalence of prescriptions for each drug with the highest level of evidence and estimating the prevalence of potentially actionable prescribing decisions.
This randomized clinical trial investigates whether routine CYP2D6 and CYP2C19 genotyping affects the persistence of antipsychotic drug treatment among adults with schizophrenia.
This randomized clinical trial examines the impact of delivering SLCO1B1 pharmacogenetic results to physicians on low-density lipoprotein cholesterol levels and concordance with prescribing guidelines for statin safety and effectiveness.
This open-label randomized trial compares the effect of a genotype-guided oral P2Y12 inhibitor selection strategy vs conventional clopidogrel prescribing on 12-month ischemic outcomes after percutaneous coronary intervention (PCI) in CYP2C19*2/CYP2C19*3 loss-of-function allele carriers with acute coronary syndromes and stable cardiovascular disease.
This phase 2 randomized clinical trial evaluates the effect of combined selective cyclooxygenase 2 (COX-2) inhibition with standard concurrent chemoradiation therapy vs concurrent chemoradiation alone on survival among patients with unresectable stage III non–small cell lung cancer (NSCLC).
This study investigates whether mandatory reporting of CYP2C19 metabolizer status influence physicians’ decisions to switch P2Y12 inhibitors in the context of a clinical trial.
This cross-sectional study uses 1000 Genomes Project data and US Veterans Health Administration demographic characteristics to project the number of veterans who carry an actionable pharmacogenetic variant and who have been prescribed 1 or more level A drugs that have well-established evidence of pharmacogenetic interactions.
This systematic review and meta-analysis assesses whether HLA-C*06:02 status is associated with a differential response in patients with psoriasis after 6 months of ustekinumab therapy.
This cohort study examines the use of screening in Chinese patients with leprosy before dapsone treatment for the HLA-B*13:01 allele associated with dapsone hypersensitivity syndrome.
This case-control study investigates genetic variants associated with thiopurine-induced myelosuppression among patients of European ancestry with inflammatory bowel disease (IBD).
This case report describes the use of genotype-guided medical treatment of an arteriovenous malformation in a child.
Customize your JAMA Network experience by selecting one or more topics from the list below.